BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AKY-2519 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AKY-2519\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07581184-10935@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:AKY-2519: Phase 1 readout est. (NCT07581184)
DESCRIPTION:AKY-2519\, phase 1\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic C
 astration-Resistant Prostate Cancer\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/aky-2519#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07581184
URL:https://assetmemo.bio/drug/aky-2519#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887971-10935@assetmemo.bio
DTSTAMP:20261121T004551Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:AKY-2519: Phase 1 readout est. (NCT07887971)
DESCRIPTION:AKY-2519\, phase 1\, Metastatic Castration-Resistant Prostate C
 ancer.\nStudy: A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expres
 sing Solid Tumors\nEstimated primary completion: December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/aky-2519#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07887971
URL:https://assetmemo.bio/drug/aky-2519#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
